VivoSeq
Psychiatry

Postpartum Depression

46

Pipeline Programs

9

Active Trials

23

Companies Involved

Postpartum Depression is a moderately active landscape with 46 programs across 23 companies. The most active players are Pragma, Nanjing Minova Pharmaceutical Co., Ltd., Brii Biosciences Limited. 13 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

77/100

Attrition Rate

18/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

57

clinical trials

Completed33 · 58%
Terminated7 · 12%
Recruiting5 · 9%
Unknown status4 · 7%
Not yet recruiting3 · 5%
Withdrawn3 · 5%
Other2 · 4%

Trial Activity

57 trials

The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression
Active, not recruiting··Phase 1·NCT04950868·22 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)